EicOsis Human Health, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.eicosis.com
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
Phase 1
Recruiting
- Conditions
- Spinal Cord InjuriesNeuropathic Pain
- Interventions
- Drug: Placebo oral tabletDrug: EC5026 oral tablet
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06438471
- Locations
- 🇺🇸
AU Medical Center, Augusta, Georgia, United States
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: EC5026 oral tabletDrug: Placebo oral tablet
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06089837
- Locations
- 🇳🇿
New Zealand Clinical Research, Christchurch, New Zealand
Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- Drug: EC5026 oral tabletOther: Placebo oral tablet
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04908995
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
- Conditions
- COVID-19
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04452942
- Locations
- 🇺🇸
Stony Brook University Hospital, New York, New York, United States
Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- Drug: EC5026 oral capsuleOther: Placebo oral capsule
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04228302
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath